Clinical Trial Update: Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patients (FrEDI) Study [NA]

View source ↗

Summary

Clinical trial update announcing completion of the FrEDI study evaluating Fosrenol (lanthanum carbonate) for enhancing dietary protein intake in hypoalbuminemic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• FOSRENOL (lanthanum carbonate)

Snippet

Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Conditions: End-Stage Renal Disease | NA | Status: COMPLETED